Ensemble Therapeutics Corporation

Ensemble Therapeutics Extends Macrocycle Drug Discovery Alliance with Bristol-Myers Squibb

Ensemble Therapeutics Extends Macrocycle Drug Discovery Alliance with Bristol-Myers Squibb

January 5, 2012

CAMBRIDGE, MA – January 5, 2012 -- Ensemble Therapeutics, a biotechnology company developing EnsemblinsTM, a novel class of small molecule therapeutics with the power of biologics, announced today the extension of its strategic alliance with Bristol-Myers Squibb (NYSE: BMS), building on a collaboration initiated in April 2009.

CIA's In-Q-Tel makes strategic investment in Quanterix

CIA's In-Q-Tel makes strategic investment in Quanterix

January 5, 2012

Quanterix Corp. has taken a strategic investment for an undisclosed amount from In-Q-Tel, the investment arm of the CIA, to help expand development of its technology to detect pathogens.

Please click on Mass High Tech logo to view full article

Drawing blood with a tap, not a sting - Cambridge firm’s device uses tiny needles, vacuum for painless diagnostic tests

Drawing blood with a tap, not a sting - Cambridge firm’s device uses tiny needles, vacuum for painless diagnostic tests

January 2, 2012

Pop culture has developed an appetite for blood, but the average American still cowers at the sight of a needle.

What if giving blood was as easy and painless as a tap on the arm? Engineers at Seventh Sense Biosystems in Cambridge have been working for two years to make that so. And they are getting close.
 

Please click on Boston.com logo to view full article.

 

Acceleron Pharma, Inc.

Acceleron Secures $30M Private Financing

Acceleron Secures $30M Private Financing

December 23, 2011

CAMBRIDGE, Mass. – December 23, 2011 –  Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced it raised a $30M private financing.  Celgene, one of Acceleron’s strategic partners, and all other existing investors participated in this financing.  The proceeds will be used to expand and advance Acceleron’s clinical stage pipeline and to continue to support its highly productive research engine.
 

BG Medicine, Inc.

BG Medicine, Inc. Files 510(k) for AMIPredict

BG Medicine, Inc. Files 510(k) for AMIPredict

December 28, 2011

WALTHAM, Mass., Dec. 28, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that it has filed a 510(k) Premarket Notification with the U.S. Food and Drug Administration (FDA) for regulatory clearance of the company's second cardiovascular diagnostic test, AMIPredict. The filing was made following the successful completion of a validation study using data from the company's BioImage Study, which involved approximately 6,600 individuals.

Quanterix Corporation

Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology

Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology

December 22, 2011

CAMBRIDGE, Mass., Dec. 22, 2011 /PRNewswire/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, has reported a method for detecting individual proteins within microfabricated polymer arrays produced by Sony DADC.  Quanterix recently entered into a collaboration with Sony DADC for the development and manufacture of "smart consumables" based on an optical disc format.  This method was published online in Lab on a Chip.

Seventh Sense Biosystems, Inc.

Seventh Sense Biosystems Receives $3.28 Million Grand Challenges Point-of-Care Diagnostics Grant to Expand Touch Activated Phlebotomy(TM) Technology Platform

Seventh Sense Biosystems Receives $3.28 Million Grand Challenges Point-of-Care Diagnostics Grant to Expand Touch Activated Phlebotomy(TM) Technology Platform

December 16, 2011

CAMBRIDGE, Mass., Dec 16, 2011 (BUSINESS WIRE) -- Seventh Sense Biosystems, Inc., a company developing novel blood sampling technology for decentralized diagnostic testing, announced today that it has been awarded a $3.28 million grant from the Bill & Melinda Gates Foundation. The grant is part of the Grand Challenges in Global Health initiative to seek out innovative ideas for diagnostics in the developing world.

Abbie Celniker - FierceBiotech's 2011 Women in Biotech

Abbie Celniker - FierceBiotech's 2011 Women in Biotech

November 29, 2011

Abbie Celniker has landed back on startup turf at Eleven Biotherapeutics, where she was just named CEO in September. She's now bringing her two decades of experience in biotech drug development to complement the protein engineering hotshots on staff, and all have ambitious goals to advance new protein drugs to treat a slate of diseases such as dry eye. Money helps. So Celniker has also been busy talking to investors and working with the business team on partnering plans.

Click logo to view full article

 

Quanterix Corporation

Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin

Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin

December 1, 2011

CAMBRIDGE, Mass., Dec. 1, 2011 /PRNewswire via COMTEX/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA(TM)) technology, announced today that it has been awarded a one year $250,155 contract from the Department of Homeland Security (DHS) to develop an assay capable of detecting single molecules of botulinum toxin (BoNT) within complex environmental samples.

Receptos, Inc.

Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research

Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research

December 12, 2011

SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- Receptos Inc. announced today the establishment of a collaboration with Ono Pharmaceutical Co., Ltd. (Osaka, Japan) for the research and development of small molecule modulators of an undisclosed G-protein coupled receptor (GPCR) target. Under the terms of the agreement, Receptos will use its proprietary technology platform to produce high resolution protein crystal structures of the discovery target and drive Ono's structure-based drug design efforts.